

Jo Brewer, PhD
VP Allogeneic Research
ASGCT 22nd
Annual Meeting
May 2, 2019

Differentiating T-Cells from hiPSCs to Create Off-the-Shelf SPEAR T-Cell Therapies


Lee Carpenter, Laura Barker, Adam Sidaway, Cheng-Tao Yang, Ellen Koerner, Rosanna McEwen-Smith, Claire Gueguen, Natalie Bath, William Spinner, Alex Tipping, Katie Bardsley, Garth Hamilton, Ryan Wong, Joanna Brewer
Adaptimmune, Abingdon, Oxfordshire, UK, and Philadelphia, PA, USA

Disclosures

- All authors are employed by and have stock or other ownership interests in Adaptimmune

Autologous T-cell manufacturing

A. Autologous SPEAR T-cell treatment



Factors that can affect the autologous product are:

- Complex patient scheduling and supply chain
- Long lead time for individual products to be manufactured and released
- Patient leukapheresis is variable and hard to control
 - Cell composition
 - Age
 - Prior treatment regimens

Advantages of manufacturing an off-the-shelf T-cell product


B. Off-the-shelf SPEAR T-cells derived from hiPSCs




- Routine patient scheduling and supply chain
- Products manufactured and released ahead of need, stored cryogenically (off-the-shelf)
- Product highly characterized
 - Defined cell composition
 - Demonstrated efficacy
 - Known safety profile
 - Reasonable cost of goods

Our research aims to make off-the-shelf T-cell products a reality

- Key process features
 - hiPSC-directed differentiation without murine stroma
 - Enabling scale-up and GMP manufacture of edited off-the-shelf lines
- hiPSCs are able to differentiate through multiple precursor stages toward a mature T-cell phenotype *in vitro*



A ready, reproducible supply of T-cells from a single, well-characterized source




CD3/TCR
mature T-cell


- hiPSC-derived T-cells display hallmark features of mature T-cells
 - Expression of lineage-specific genes (Biomark panel)
 - Surface TCR $\alpha\beta$ or TCR $\gamma\delta$ expression (flow cytometry)
 - Effector functions: cytokines, lytic granules, and CD69 upregulation

Starting with hiPSC before differentiation


Assessment of pluripotency




TRA-160 (red) Oct4 (green) nuclei (blue)





Oct4



Nanog




TRA-160




Generating CD34⁺CD45⁺ hematopoietic progenitors and early pro-T-cells...


Intermediate developmental stages




HSC
blood lineages




CD34 (red) CD45 (green) nuclei (blue)




CD34 (red) CD45 (green) nuclei (blue)




CD34 (red) CD3 (green) nuclei (blue)




CD4/8
DP immature T-cell



CD8 (red) CD4 (green) nuclei (blue)



Brightfield



CD3 (green) nuclei (blue)







CD3/TCR
mature T-cell

...and finally to T-cells

Intermediate-stage
T-cell
progenitors







CD4/8
DP immature T-cell




End-of-
process
differentiated
T-cells



CD3/TCR
mature T-cell




Transcriptional profiling of hiPSC- and cord-derived CD3⁺ T-cells together with peripheral T-cells reveals similar gene signatures





Functionality of stem cell–derived T-cells following stimulation with PMA/ionomycin

Gated on CD3⁺ population



TCR-transduced hiPSC-derived T-cells are activated in an antigen-dependent manner



Conclusions

- These hiPSC-derived T-cells show many characteristics that make them ideal for allogeneic, off-the-shelf T-cell therapies for oncology
 - Typical T-cell marker expression mimicking mature peripheral blood T-cells
 - Cytokine production after stimulation
 - Lytic granule production and release after stimulation
 - Tumor antigen-specific activation of TCR signaling pathway when engineered to express SPEAR TCR
 - Consistent batches can be manufactured to treat multiple patients
- This source of T-cells, when combined with genetic engineering to enhance tumor recognition with SPEAR TCR and prevent GVHD by preventing endogenous TCR expression, could accelerate a new generation of off-the-shelf T-cell therapies

Acknowledgments

- We thank the High-Throughput Genomics Group at the Wellcome Trust Centre for Human Genetics (funded by Wellcome Trust grant reference 203141/Z/16/Z) for the generation and initial processing of the array data
- Takara Bio Europe AB (Sweden) for the use of their hiPSC cell line ChiPSC31
- Universal Cells, Inc. an Astellas company
- Adaptimmune team
 - Lee Carpenter
 - Katie Bardsley
 - Adam Sidaway
 - Cheng-Tao Yang
 - Gulsum Sivacki
 - Ellen Koerner
 - Sunniva Bostrand
 - Garth Hamilton
 - Bon Ham Yip
 - Ryan Wong
 - Rosanna McEwen-Smith
 - Claire Gueguen
 - Laura Barker
 - Natalie Bath
 - William Spinner
 - Alex Tipping
 - Peter Mitchell
 - Jennifer Man
 - Jaqueline Viera
 - Darius Pillsbury
 - Michael Blackton
 - Phil Bassett
 - Mark Tatlock
 - Will Trigg
 - Chris Barnes
 - Barbara Tavano
 - Dennis Williams
 - Andrew “Jez” Gerry
 - Tom Holdich
 - Rafael Amado